Project Details
Description
A Phase III Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infection in Adult,
| Status | Finished |
|---|---|
| Effective start/end date | 6/11/14 → 12/31/17 |
Funding
- MERCK AND CO INC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.